Rebamipide


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Gastritis; Peptic ulcer 100 mg tid.
Dosage Details
Oral
Gastritis, Peptic ulcer
Adult: 100 mg tid, in the morning, evening and before bedtime.
Administration
May be taken with or without food.
Special Precautions
Pregnancy and lactation. Elderly.
Adverse Reactions
Dizziness, drowsiness, dry mouth, constipation, diarrhoea, abdominal distention, nausea, vomiting, eructation; ALT, AST and BUN elevation, oedema, hyperbilirubinaemia; gynaecomastia, induction of lactation, menstrual disorders, hot flushes; leucopenia, leucocytosis, thrombocytopenia; rash, urticaria, eczema.
Action
Description: Rebamipide is a mucosal protective agent and is postulated to increase gastric blood flow, prostaglandin biosynthesis and decrease free oxygen radicals.
Pharmacokinetics:
Absorption: Time to peak plasma concentration: 2 hr.
Distribution: Plasma protein binding: Approx 98%.
Excretion: Via urine (approx 10%) as unchanged drug. Plasma elimination half-life: Approx 1.5 hr.
Storage
Store below 25°C.
ATC Classification
A02BX14 - rebamipide ; Belongs to the class of other drugs used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
References
Anon. Rebamipide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/12/2015.

Buckingham R (ed). Rebamipide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/12/2015.

Mucosta (Otsuka). MIMS Philippines. http://www.mims.com/philippines. Accessed 01/12/2015.

Disclaimer: This information is independently developed by MIMS based on Rebamipide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in